KR102449712B1 - 아미노티아졸 화합물 및 이의 용도 - Google Patents

아미노티아졸 화합물 및 이의 용도 Download PDF

Info

Publication number
KR102449712B1
KR102449712B1 KR1020187024997A KR20187024997A KR102449712B1 KR 102449712 B1 KR102449712 B1 KR 102449712B1 KR 1020187024997 A KR1020187024997 A KR 1020187024997A KR 20187024997 A KR20187024997 A KR 20187024997A KR 102449712 B1 KR102449712 B1 KR 102449712B1
Authority
KR
South Korea
Prior art keywords
alkyl
compound
atom bonded
compounds
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187024997A
Other languages
English (en)
Korean (ko)
Other versions
KR20180132618A (ko
Inventor
위어-톰 지앙
츠 수
Original Assignee
내셔날 헬스 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 내셔날 헬스 리서치 인스티튜트 filed Critical 내셔날 헬스 리서치 인스티튜트
Publication of KR20180132618A publication Critical patent/KR20180132618A/ko
Application granted granted Critical
Publication of KR102449712B1 publication Critical patent/KR102449712B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020187024997A 2016-02-05 2017-01-31 아미노티아졸 화합물 및 이의 용도 Active KR102449712B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291667P 2016-02-05 2016-02-05
US62/291,667 2016-02-05
PCT/US2017/015765 WO2017136315A1 (en) 2016-02-05 2017-01-31 Aminothiazole compounds and use thereof

Publications (2)

Publication Number Publication Date
KR20180132618A KR20180132618A (ko) 2018-12-12
KR102449712B1 true KR102449712B1 (ko) 2022-09-30

Family

ID=59496120

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187024997A Active KR102449712B1 (ko) 2016-02-05 2017-01-31 아미노티아졸 화합물 및 이의 용도

Country Status (8)

Country Link
US (1) US10047078B2 (enExample)
EP (1) EP3411035B1 (enExample)
JP (1) JP6883049B2 (enExample)
KR (1) KR102449712B1 (enExample)
CN (1) CN109069504B (enExample)
ES (1) ES2909612T3 (enExample)
TW (1) TWI620748B (enExample)
WO (1) WO2017136315A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
CN112469414A (zh) 2018-05-25 2021-03-09 昂科库博疗法有限责任公司 作为新型候选抗癌药物的高效力tacc3抑制剂
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
KR20240005751A (ko) * 2021-04-12 2024-01-12 에이2에이 파마수티칼스, 잉크. 암 치료를 위한 조성물 및 방법
CA3246244A1 (en) 2022-03-24 2023-09-28 A2A Pharmaceuticals, Inc. CANCER COMPOSITIONS AND TREATMENT METHODS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225880A1 (en) * 2011-03-04 2012-09-06 National Health Research Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2366932C (en) * 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
ES2257461T3 (es) * 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
EP1558609A4 (en) * 2002-10-30 2008-05-28 Merck & Co Inc KINASE INHIBITORS
KR100919905B1 (ko) * 2005-01-26 2009-10-06 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
AU2008355098B2 (en) 2008-04-21 2012-11-15 Gpcr Therapeutics, Inc Heterocyclic compounds
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
ES2570177T3 (es) 2010-08-10 2016-05-17 Astellas Pharma Inc Compuesto heterocíclico
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
CN104024246B (zh) * 2012-03-27 2016-03-02 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225880A1 (en) * 2011-03-04 2012-09-06 National Health Research Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors

Also Published As

Publication number Publication date
TW201728583A (zh) 2017-08-16
US20170226100A1 (en) 2017-08-10
ES2909612T3 (es) 2022-05-09
KR20180132618A (ko) 2018-12-12
EP3411035B1 (en) 2022-03-02
EP3411035A1 (en) 2018-12-12
CN109069504B (zh) 2022-06-28
TWI620748B (zh) 2018-04-11
JP2019511564A (ja) 2019-04-25
US10047078B2 (en) 2018-08-14
WO2017136315A1 (en) 2017-08-10
EP3411035A4 (en) 2019-08-14
HK1258689A1 (zh) 2019-11-15
JP6883049B2 (ja) 2021-06-02
CN109069504A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
US10047078B2 (en) Aminothiazole compounds
JP7058345B2 (ja) Ｂｃｌ－２阻害剤及びＭＤＭ２阻害剤の組合せ製品並びに疾患の予防及び／又治療におけるその使用
KR20240019172A (ko) Mat2a 억제제 및 유형 ii prmt 억제제를 포함하는 병용 요법
TW202144345A (zh) Ｋｒａｓ突變蛋白抑制劑
TWI726362B (zh) Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或Bcl-2抑制劑與CHOP聯合用藥的協同抗腫瘤作用
KR20200138724A (ko) Bcl-2 억제제 또는 Bcl-2/Bcl-xL 이중 억제제와 BTK 억제제의 병용 제품 및 질환의 예방 및/또는 치료에 있어서 이의 용도
BR112012004453A2 (pt) Composto inibidor de proteína quinase, sua composição farmacêutica e seu uso
WO2016168704A1 (en) Ksr antagonists
KR102372288B1 (ko) 단백질 키나아제 억제제로서의 아미노티아졸 화합물
JP2024521788A (ja) 併用療法
JP2018508563A (ja) Ｕｓｐ７阻害剤化合物及び使用方法
CN110072526A (zh) 治疗癌症的激酶抑制剂化合物、组合物和方法
AU2020300619A1 (en) Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
Gao et al. Synthesis and evaluation of osimertinib derivatives as potent EGFR inhibitors
JP6913955B2 (ja) ＰＩ３Ｋ／ｍＴＯＲ阻害剤としての溶融キノリン化合物
WO2015112705A2 (en) Therapeutic combinations for treating cancer
AU2017295858A1 (en) Treatment of cancer
CN112237579B (zh) 药物组合及其用途
WO2022268065A1 (en) Compounds as erk inhibitors
JP7200453B2 (ja) Ａｘｌ阻害剤として使用するためのピリドピリミジノン誘導体
JP6782710B2 (ja) Ｒａｃ−ＧＴＰアーゼ媒介性障害を処置するための化合物
US20250042918A1 (en) Compounds
HK1258689B (en) Aminothiazole compounds and use thereof
KR20240128955A (ko) 암 치료제로서의 강력하고 선택적인 smarca2 분해 키메라 분자
EA043296B1 (ru) Производные пиридопиримидинона для применения в качестве ингибиторов axl

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4